Osmotica Pharmaceutical is a fully-integrated pharmaceutical company with demonstrated expertise in developing commercially successful products. As one of the world's leading osmotic drug delivery companies, we leverage our significant resources in R&D and proprietary drug delivery technology to address the growing need of the global patient population.
We have the resources and experience to successfully commercialize our products through our subsidiaries, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC.
For more company information, please visit our websites:
www.Osmotica.com
www.VerticalPharma.com
www.TrigenLab.com
We have the resources and experience to successfully commercialize our products through our subsidiaries, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC.
For more company information, please visit our websites:
www.Osmotica.com
www.VerticalPharma.com
www.TrigenLab.com
Location: United States, New Jersey
Employees: 201-500
Founded date: 2000
Investors 1
| Date | Name | Website |
| 23.01.2022 | Avista Cap... | avistacap.... |
Mentions in press and media 15
| Date | Title | Description |
| 28.04.2023 | RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing | BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) — RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solu... |
| 29.01.2022 | Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quart... | BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“OSMT” or the “Company”), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc ... |
| 13.10.2021 | Osmotica Pharmaceuticals : plc Announces Closing of $35 Million Underwritten Public Offering | BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced... |
| 13.10.2021 | Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering | BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced... |
| 13.10.2021 | Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering | BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced... |
| 07.10.2021 | Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million | BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to... |
| 07.10.2021 | Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering | BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public ... |
| 07.10.2021 | Osmotica Pharmaceuticals : Announces Debt Financing from Athyrium Capital Management of up to $100 Million | BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to... |
| 07.10.2021 | Osmotica Pharmaceuticals : Announces Pricing of $35 Million Underwritten Public Offering | BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public ... |
| 19.02.2018 | FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults | Bridgewater, NJ – February 19, 2018 – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its proprietary osmotic... |
Show more